Explore

Reuters Reuters
Instant View: Cannabis rescheduling fuels optimism across industry

Instant View: Cannabis rescheduling fuels optimism across industry

April 23 (Reuters) - The U.S. Department of Justice is immediately loosening restrictions on some marijuana products and accelerating the process of reclassifying the drug as less dangerous in one of the biggest changes to U.S. drug policy in decades.
Reuters Reuters
White House to announce drug pricing deal with Regeneron

White House to announce drug pricing deal with Regeneron

By Sriparna Roy WASHINGTON, April 23 (Reuters) - The White House will announce a drug pricing deal with Regeneron Pharmaceuticals at an event on Thursday afternoon, White House press ⁠secretary Karoline Leavitt said in a post on X.
Reuters Reuters
Wall Street futures mixed as US-Iran stalemate keeps investors on edge

Wall Street futures mixed as US-Iran stalemate keeps investors on edge

April 24 (Reuters) - Wall Street futures were mixed on Friday, with markets heading toward the end of a week overshadowed by the U.S.-Iran stalemate that extinguished hopes of a swift end to the war.
Reuters Reuters
Explainer-How US marijuana reclassification could help cannabis companies

Explainer-How US marijuana reclassification could help cannabis companies

By Mariam Sunny and Suzanne McGee April 22 (Reuters) - The U.S. administration is expected to reclassify marijuana as a less dangerous drug as soon as Wednesday, Axios reported, citing an official familiar with the matter.
Reuters Reuters
Pot firms rally after US reclassifies marijuana as less dangerous drug

Pot firms rally after US reclassifies marijuana as less dangerous drug

By Mrinalika Roy and Christy Santhosh April 23 (Reuters) - Shares of cannabis firms surged on Thursday after the U.S. government moved to reclassify the Food and Drug Administration-approved and state-licensed marijuana as a less-dangerous drug.
Reuters Reuters
Explainer-What to know about psychedelic therapies cited by Trump

Explainer-What to know about psychedelic therapies cited by Trump

By Nancy Lapid April 21 (Reuters) - U.S.
Reuters Reuters
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

By Ahmed Aboulenein and Puyaan Singh WASHINGTON, April 22 (Reuters) - Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had nothing to do with the U.S.
Reuters Reuters
D.R. Horton beats annual revenue forecast estimates despite tepid home sales

D.R. Horton beats annual revenue forecast estimates despite tepid home sales

April 21 (Reuters) - D.R. Horton's narrowed forecast for annual revenue still came in above analysts' estimates, despite high interest rates and inflation weighing on the homebuilder's margins. Shares of D.R. Horton were up nearly 4% before the bell on Tuesday.
Reuters Reuters
Investor Justin Sun sues Trump-backed World Liberty Financial over token rights

Investor Justin Sun sues Trump-backed World Liberty Financial over token rights

April 21 (Reuters) - Crypto entrepreneur Justin Sun filed a lawsuit on Tuesday against U.S. President Donald Trump's World Liberty Financial in California federal court, seeking to unfreeze his WLFI tokens and block the venture from seizing, burning or curbing them.
Reuters Reuters
European shares rise as Trump extends Iran ceasefire; corporate earnings on tap

European shares rise as Trump extends Iran ceasefire; corporate earnings on tap

April 22 (Reuters) - European shares climbed on Wednesday as traders responded positively to U.S. President Donald Trump's announcement of an indefinite ceasefire with Iran, while investors also parsed a raft of regional corporate earnings reports.
Reuters Reuters
US FDA approves Merck's pill combo to treat HIV infection

US FDA approves Merck's pill combo to treat HIV infection

April 21 (Reuters) - The U.S. Food and Drug Administration has approved Merck's once-daily, oral, combination regimen for HIV infections, the health regulator's website showed on Tuesday.
Reuters Reuters
Fed rate cut pushed back to late 2026 on war-related inflation risks: Reuters poll

Fed rate cut pushed back to late 2026 on war-related inflation risks: Reuters poll

By Indradip Ghosh BENGALURU, April 22 (Reuters) - The U.S. Federal Reserve will wait at least six months before cutting interest rates this year, according to a Reuters poll of economists, as war-driven energy shocks reignite already-elevated inflation.